Primary (essential) hypertension
Conditions
Brief summary
Predictive value of a MOMICs profile to discriminate subjects with a decrease in 24-hour blood pressure below the median from subjects with a decrease in 24-hour blood pressure above the median for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine).
Detailed description
Predictive value of a MOMICs profile to discriminate subjects with a decrease in night-time blood pressure below the median from subjects with a decrease in 24-hour blood pressure above the median, for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine)., Correlation between changes in individual biomarkers and adverse effects as documented using adverse effects questionnaire and SF-36
Interventions
DRUGOlmesartan medoxomil/Amlodipine Aurobindo 20 mg/5 mg
DRUGfilmomhulde tabletten
DRUGOlmesartan medoxomil Glenmark 40 mg filmomhulde tabletten
DRUGHydrochloorthiazide Mylan 25 mg
DRUGtabletten
DRUGAmlodipine (als besilaat) Sandoz 10 mg
Sponsors
Stichting Radboud University Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Predictive value of a MOMICs profile to discriminate subjects with a decrease in 24-hour blood pressure below the median from subjects with a decrease in 24-hour blood pressure above the median for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine). | — |
Secondary
| Measure | Time frame |
|---|---|
| Predictive value of a MOMICs profile to discriminate subjects with a decrease in night-time blood pressure below the median from subjects with a decrease in 24-hour blood pressure above the median, for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine)., Correlation between changes in individual biomarkers and adverse effects as documented using adverse effects questionnaire and SF-36 | — |
Countries
Netherlands
Outcome results
None listed